Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection.
After 2 weeks of intravenous challenge with Mycobacterium simiae, ICR outbred mice were treated with clarithromycin, ofloxacin, or clarithromycin plus ethambutol for 4 weeks. All three therapy groups demonstrated a decrease in the level of infection in both the lungs and the spleen. There were no significant differences among the three treated groups in decreasing mycobacterial counts in the lungs; however, both ofloxacin and clarithromycin plus ethambutol were superior to clarithromycin alone in reducing the level of infection in the spleen. Results of the study suggest a potential role for these agents in the treatment of human M. simiae infection.
Valero
G
G
Department of Infectious Diseases, Audie L. Murphy Memorial Veterans Hospital, San Antonio, TX 78284.
Moreno
F
F
Graybill
J R
JR
D000818:Animals; D017291:Clarithromycin / Q000494:pharmacology*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D009161:Mycobacterium / Q000187:drug effects*; D015242:Ofloxacin / Q000494:pharmacology*; D017192:Skin Diseases, Bacterial / Q000188:drug therapy* / Q000473:pathology; D013158:Splenic Diseases / Q000188:drug therapy* / Q000473:pathology
D004977:Ethambutol; D015242:Ofloxacin; D017291:Clarithromycin